
Results
15
Companies which are more than 50% undervalued based on analyst price target.
15 companies
Nanobiotix
Market Cap: €1.8b
Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
NANO
€34.76
7D
4.0%
1Y
660.6%
Inventiva
Market Cap: €914.4m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.87
7D
2.9%
1Y
40.2%
Valneva
Market Cap: €412.9m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.18
7D
-4.6%
1Y
-21.0%
Cellectis
Market Cap: €176.7m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.43
7D
-8.0%
1Y
49.0%
Innate Pharma
Market Cap: €147.9m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.58
7D
-1.0%
1Y
0.8%
Sensorion
Market Cap: €139.0m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.27
7D
8.0%
1Y
-10.9%
OSE Immunotherapeutics
Market Cap: €78.1m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.32
7D
-1.2%
1Y
-36.2%
Adocia
Market Cap: €76.7m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.92
7D
2.8%
1Y
-13.5%
ABIONYX Pharma
Market Cap: €65.6m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.86
7D
0.3%
1Y
51.2%
MaaT Pharma
Market Cap: €52.0m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.76
7D
6.2%
1Y
-39.2%
AB Science
Market Cap: €51.6m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.65
7D
-12.8%
1Y
-49.8%
Nicox
Market Cap: €33.7m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.38
7D
-0.1%
1Y
69.0%
Advicenne
Market Cap: €25.3m
A specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
ALDVI
€1.74
7D
3.9%
1Y
28.8%
GenSight Biologics
Market Cap: €18.8m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.08
7D
-4.5%
1Y
-33.6%
Valbiotis
Market Cap: €18.5m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.78
7D
-3.0%
1Y
-11.0%